Fexofenadine Completed Phase 4 Trials for Allergic Rhinitis (AR) Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02175485Evaluation of Efficacy of Dellegra in Exposure Unit
NCT00636870Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine
NCT00637585Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
NCT00638118Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen
NCT02551536Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis